EZH2 and diffuse large B-cell lymphoma: As expected, 1 treatmentdose-dependently decreased the protein levels of EZH2, EED, and SUZ12in both the DB (EZH2 mutant) and Toledo (wild-type EZH2) cell lines,which was in agreement with the reported effects of mutations ableto disrupt these protein–protein interactions.24,70 Furthermore, low micromolar concentrations of 1 markedlyimpaired the proliferation of GCB-DLBCL cells carrying mutant or wild-typeforms of EZH2.